Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution

NCT01266265 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT01266265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Lead sponsor
United Therapeutics
Phase
Observational
Overall status
Completed
Start date
December 31, 2010
Completion date
December 31, 2014
Enrollment
1,333 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension